In subgroup analyses ET on BC risk, no modification effect and difference showed on duration of ET use, time since last use, race/ethnicity, estrogen type, subjects and expression of ER and PR, invasive or not (all P interaction > 0.05). Nevertheless, the statistically elevated risk of BC was observed when duration of ET use extended to more than 10 years, compared with duration in less than 10 years. The BC RRs for participants at < 50, 50-60, > 60 years at studies entry were respectively 1.37 (95% CI = 1.05-1.68, I 2 = 70.4%, P heterogeneity = 0.03, n = 3), 1.19 (95% CI = 1.07-1.31, I 2 = 70.6%, P heterogeneity < 0.01, n = 9), 1.08(95% CI = 0.92-1.24, I 2 = 70.6%, P heterogeneity < 0.001, n = 7), and marginal interaction effect was found (P interaction = 0.07). Meanwhile, the risk of BC among ET users varied substantially (P interaction < 0.01) according to BMI of subjects. There was moderate increased risk (RR = 1.40, 95% CI = 1.27-1.54, n = 9) at low and normal BMI rang down to a BMI of 25kg/m 2
, but risk disappeared in the overweight (BMI of 25-30 kg/m 2 ) and obesity (BMI of > 30 kg/m 2 ) categories. On the basis of limited studies, different routes of administration potentially affected BC risk (P interaction = 0.02), one of which exerted a protectable effect on BC incidence when women using ET vaginally (RR=0.88, 95% CI = 0.79-0.98, n = 2). Furthermore, this association was considerably stronger among postmenopausal women (RR=1.19, 95% CI = 1.15-1.24, n = 13), but failed to find significant associations when restricting women to those undergoing surgeries or naturally menopause. As for characteristics of BC, BC risk differed between ductal (RR= 1.11, 95% CI = 0.99-1.23, I 2 = 69.1%, P heterogeneity < 0.01, n = 8) and lobular (RR = 1.56, 95% CI=1.38-1.73, I 2 = 0, P heterogeneity = 0.69, n = 7) carcinoma(P interaction < 0.01). When restricting dose-response meta-analysis for participants with BMI < 25 kg/m 2 , there was no dose-response relationship between duration of use and BC risk (RR for per year increase in duration of ET use = 1.03, 95% CI = 1.02-1.03, goodness-of-fit chi 2 18 = 27.85, P goodness-of-fit = 0.06, n =6), and a linear curve on this relationship was found (P non-linearity = 0.12) (eFigure 1A in the Supplementary). Similarly, no dose-response associations between duration of ET use and the risk of BC among overweight and obesity participants (BMI > 25 kg/m 2 ) was reveled through a linear random-effect dose-response model (RR for per year increase in duration of use=1.01, 95% CI = 1.00-1.01, goodness-of-fit chi 2 18 = 15.58, P goodness-of-fit = 0.62, n = 6), and a linear curve was detected (P non-linearity =0.53) (eFigure.1B in the Supplementary). Based on association of current ET use and the risk of BC, omitting one study in turn did not significantly change the summary risk estimate of BC, with the pooled RRs ranging from 1.14 (95% CI = 1.07 to 1.22) 1 to 1.18 (95% CI = 1.10 to 1.27) 2 . Furthermore, no evidence of publication bias for this relationship was found by Begg's test and Egger's test (all P > 0.05).
EPT and the risk of BC
It seems that only duration of EPT use, race/ ethnicity and type of combined regimen can explain the high heterogeneity for relationship of EPT with the increased BC risk (all P interaction < 0.05). The summary RRs showed stronger with long time use (> 10 years), ER positive or lobular BC (RR= 2.03, 1.97, 2.24, 95% CI=1.66-2.40, 1.59-2.35, 1.39-3.09, respectively). Remarkably, some variables like BMI, age at entry and type of combined regimen were critically potential modifiers (all P interaction < 0.1), and a significant higher BC risk was observed in a thinner and younger woman using continuous EPT regimens. When further investigating modification effect of BMI or gap time on dose-response analyses for duration of use, similar magnitudes were observed among low BMI (< 25 kg/m 2 ) (RR for per year increase in duration of use = 1.06, 95% CI = 1.05-1.06, goodness-of-fit chi 2 12 = 61.10, P goodness-of-fit < 0.001, n = 5) (P non-linearity = 0.001) (eFigure 2A in the Supplementary) and high BMI (> 25 kg/m 2 ) participants (RR for per year increase in duration of use=1.05, 95% CI = 1.04-1.06, goodness-of-fit chi 2 12 =28.42, P goodness-of-fit < 0.01, n = 5) (P non-linearity =0.49) (eFigure 2B in the Supplementary). Additionally, we identified that doseresponse curve for the relationship of duration of EPT use with BC risk was linear in users with gap time < 5 years (RR for per year increase in duration of use = 1.11, 95% CI = 1.10-1.11, goodness-of-fit chi 2 12 = 198.76, P goodness-of-fit < 0.001, n = 3) (P non-linearity = 0.57) (eFigure.3A in the Supplementary) and in those with gap time > 5 years (RR for per year increase in duration of use = 1.07, 95% CI = 1.05-1.09, goodness-of-fit chi 2 12 = 14.38, P goodness-of-fit = 0.01, n = 2) (P non-linearity =0.41) (eFigure3B in the Supplementary). Regarding to association between current EPT use and the risk of BC, each study omitting in turn did not alter the initial outcome, with magnitude changing from 1.75 (95% CI = 1.57 to 1.96) 3 
Other HRT regimens and BC risk
Either mixed HRT regimens or tibolone was associated with increased BC risk (RR for mixed HRT regimens = 1.50, 95% CI = 1.33-1.67, I 2 = 91.3%, P heterogeneity < 0.001, n = 20; RR for per year increase in duration of mixed HRT regimens use = 1.04, 95% CI PubMed search strategy with superior search capabilities was adapted for use with the other databases. Items were found from EMBASE database (n = 2071) and Web of Science database (n = 1325) until Jan 3, 2017. 
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1 "Selection" part includes representativeness of cases, selection of controls, exposure ascertainment, and no breast cancer incident when investigation begin. 2 "Comparability" part includes comparable on confounders.
3 "Outcome" part includes outcome assessment, adequate follow-up, and loss to follow-up rate. 4 The total score is equal to the total number of stars. 5 The exposed cohorts are population-based or hospital-based, which can award a star. Population coming from nurses, volunteers or unknown sources cannot award a star. 6 Only the same source with exposed cohorts, the non-exposed cohorts are considered as selected. 7 When exposure variables should be ascertained by medical records or questionnaires, a star should be awarded. 8 If the studies adjusted for two individual factors among age, menopausal age, family history of breast cancer, mammographic screening, it is award a star. If the studies adjusted for two lifestyle factors among body mass index, physical activity, smoking status and alcohol consumption, it is award another star. 9 When breast cancer cases were identified by cancer registry, pathological proving or medical records, a star should be awarded. 

